AXGN Quote, Financials, Valuation and Earnings

IRIDEX Corp. has a net margin of 1.18% compared to Axogen, Inc.'s net margin of -12.6%. Axogen, Inc.'s return on equity of -1.94% beat IRIDEX Corp.'s return on equity of -155.93%.

Axogen, Inc. has a consensus price target of $35.44, signalling upside risk potential of 8.59%. On the other hand IRIDEX Corp. has an analysts' consensus of -- which suggests that it could grow by 75.44%. Given that IRIDEX Corp. has higher upside potential than Axogen, Inc., analysts believe IRIDEX Corp. is more attractive than Axogen, Inc..

Axogen, Inc. has a beta of 1.062, which suggesting that the stock is 6.241% more volatile than S&P 500. In comparison IRIDEX Corp. has a beta of 0.652, suggesting its less volatile than the S&P 500 by 34.842%.

Axogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen, Inc. pays -- of its earnings as a dividend. IRIDEX Corp. pays out -- of its earnings as a dividend.

Axogen, Inc. quarterly revenues are $60.1M, which are larger than IRIDEX Corp. quarterly revenues of $12.5M. Axogen, Inc.'s net income of $708K is higher than IRIDEX Corp.'s net income of -$1.6M. Notably, Axogen, Inc.'s price-to-earnings ratio is -- while IRIDEX Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen, Inc. is 7.23x versus 0.38x for IRIDEX Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Modular Medical, Inc. has a net margin of 1.18% compared to Axogen, Inc.'s net margin of --. Axogen, Inc.'s return on equity of -1.94% beat Modular Medical, Inc.'s return on equity of -220.74%.

Axogen, Inc. has a consensus price target of $35.44, signalling upside risk potential of 8.59%. On the other hand Modular Medical, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 1886.59%. Given that Modular Medical, Inc. has higher upside potential than Axogen, Inc., analysts believe Modular Medical, Inc. is more attractive than Axogen, Inc..

Axogen, Inc. has a beta of 1.062, which suggesting that the stock is 6.241% more volatile than S&P 500. In comparison Modular Medical, Inc. has a beta of -0.232, suggesting its less volatile than the S&P 500 by 123.245%.

Axogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Modular Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen, Inc. pays -- of its earnings as a dividend. Modular Medical, Inc. pays out -- of its earnings as a dividend.

Axogen, Inc. quarterly revenues are $60.1M, which are larger than Modular Medical, Inc. quarterly revenues of --. Axogen, Inc.'s net income of $708K is higher than Modular Medical, Inc.'s net income of -$7.8M. Notably, Axogen, Inc.'s price-to-earnings ratio is -- while Modular Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen, Inc. is 7.23x versus -- for Modular Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Myomo, Inc. has a net margin of 1.18% compared to Axogen, Inc.'s net margin of -36.3%. Axogen, Inc.'s return on equity of -1.94% beat Myomo, Inc.'s return on equity of -68.35%.

Axogen, Inc. has a consensus price target of $35.44, signalling upside risk potential of 8.59%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 390.2%. Given that Myomo, Inc. has higher upside potential than Axogen, Inc., analysts believe Myomo, Inc. is more attractive than Axogen, Inc..

Axogen, Inc. has a beta of 1.062, which suggesting that the stock is 6.241% more volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.

Axogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.

Axogen, Inc. quarterly revenues are $60.1M, which are larger than Myomo, Inc. quarterly revenues of $10.1M. Axogen, Inc.'s net income of $708K is higher than Myomo, Inc.'s net income of -$3.7M. Notably, Axogen, Inc.'s price-to-earnings ratio is -- while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen, Inc. is 7.23x versus 1.00x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis, Inc. has a net margin of 1.18% compared to Axogen, Inc.'s net margin of -86.59%. Axogen, Inc.'s return on equity of -1.94% beat Stereotaxis, Inc.'s return on equity of -218.3%.

Axogen, Inc. has a consensus price target of $35.44, signalling upside risk potential of 8.59%. On the other hand Stereotaxis, Inc. has an analysts' consensus of $4.20 which suggests that it could grow by 72.84%. Given that Stereotaxis, Inc. has higher upside potential than Axogen, Inc., analysts believe Stereotaxis, Inc. is more attractive than Axogen, Inc..

Axogen, Inc. has a beta of 1.062, which suggesting that the stock is 6.241% more volatile than S&P 500. In comparison Stereotaxis, Inc. has a beta of 1.472, suggesting its more volatile than the S&P 500 by 47.244%.

Axogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen, Inc. pays -- of its earnings as a dividend. Stereotaxis, Inc. pays out -- of its earnings as a dividend.

Axogen, Inc. quarterly revenues are $60.1M, which are larger than Stereotaxis, Inc. quarterly revenues of $7.5M. Axogen, Inc.'s net income of $708K is higher than Stereotaxis, Inc.'s net income of -$6.5M. Notably, Axogen, Inc.'s price-to-earnings ratio is -- while Stereotaxis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen, Inc. is 7.23x versus 7.16x for Stereotaxis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.